BOOST Pharma CEO Hans T. Schambye presented an update on BT-101 at RESI San Diego 2026.
The presentation highlighted BOOST Pharma’s development of BT-101 for severe pediatric Osteogenesis Imperfecta (OI) and the program’s progression toward pivotal Phase III development.
RESI brings together emerging life science companies, investors and strategic partners from across the global healthcare ecosystem.